OptimizeRx (OPRX) to Release Quarterly Earnings on Monday

OptimizeRx (NASDAQ:OPRX) is anticipated to post its Q1 2025 quarterly earnings results after the market closes on Monday, May 12th. Analysts expect OptimizeRx to post earnings of ($0.11) per share and revenue of $18.69 million for the quarter.

OptimizeRx Stock Performance

OPRX stock opened at $10.01 on Friday. The firm has a 50-day simple moving average of $8.14 and a two-hundred day simple moving average of $6.31. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. OptimizeRx has a one year low of $3.78 and a one year high of $14.13. The firm has a market cap of $185.11 million, a price-to-earnings ratio of -7.53 and a beta of 1.28.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. B. Riley upgraded OptimizeRx to a “strong-buy” rating in a report on Wednesday, March 12th. JMP Securities restated a “market outperform” rating and issued a $8.00 price objective on shares of OptimizeRx in a research report on Thursday, February 6th. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.06.

Insiders Place Their Bets

In other news, Director James Paul Lang bought 321,408 shares of OptimizeRx stock in a transaction dated Friday, March 14th. The stock was acquired at an average cost of $7.60 per share, with a total value of $2,442,700.80. Following the acquisition, the director now owns 389,452 shares of the company’s stock, valued at approximately $2,959,835.20. This trade represents a 472.35 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 6.10% of the stock is owned by company insiders.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.